EUVIMEDEUVIMED entdecken
Crossref

Proposed Policy Changes to Cancer Care and Oncologic Drug Reimbursement: Exploring the Rationale and Anticipating the Consequences

Ryan W Huey, Joshua C Pritchett, Kerstin N Vokinger, Wade Swenson, Tufia C Haddad, Kerin Adelson

American Society of Clinical Oncology Educational Book · 2025

DOI: 10.1200/edbk-25-473822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025. Verfasst von Ryan W Huey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Antineoplastic Agents, Health Policy, Insurance, Health, Reimbursement, Medical Oncology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although innovation in cancer treatment has improved cure rates and survival, the costs have escalated beyond societies' ability to pay. Cancer care costs in the United States are expected to rise to 245 billion by 2030. In this health policy session, we focused on three cost-containment strategies, and their potential impact on cancer care delivery. Site Neutrality: Curbing the Cost of Cancer Care, but at What Risk? , explores legislation that would introduce payment parity across differing sites of care: elimination of facility fees in hospital owned practices and shift of billing for oncology infusions away from hospital owned practices. Unintended consequences could reduce access to care for vulnerable populations, shift costs to patients, and reduce safety. Post-Pandemic Digital Health Reimbursement: Impact on Access to Care , explores how the emergency waivers, licensure flexibilities, and parity reimbursement necessitated by COVID-19 shepherded innovation that outpaced the regulatory framework needed for long-term sustainability. Today, telehealth services, hospital at home, remote patient monitoring, and decentralized clinical trial enrollment face reintroduction of regulatory and payment barriers. Will we live to see efficacy-based pricing for cancer drugs? Learning from international models , explores how lack of drug price negotiation has led to higher prices in the United States compared with Canada and Europe. Comparative clinical effectiveness pricing systems compare the value of each drug to standard treatments. Comparative cost-effectiveness programs look at the incremental cost per additional unit of health gained above the standard of care. The United States could learn from these approaches used in comparable countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsHealth PolicyInsurance, Health, ReimbursementMedical OncologyNeoplasmsReimbursement MechanismsHumansCOVID-19Health Care CostsSARS-CoV-2United States

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX.
  • Department of Oncology, Mayo Clinic, Rochester, MN.
  • Department of Community Oncology, Mayo Clinic Health System, La Crosse, WI.
  • ETH Zurich and University of Zurich, Zurich, Switzerland.
  • Department of Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND.
  • Lakewood Health System, Staples, MN.

Zitieren

APA

Huey, R. W., Pritchett, J. C., Vokinger, K. N., Swenson, W., Haddad, T. C., & Adelson, K. (2025). Proposed Policy Changes to Cancer Care and Oncologic Drug Reimbursement: Exploring the Rationale and Anticipating the Consequences. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-25-473822

Vancouver

Huey RW, Pritchett JC, Vokinger KN, Swenson W, Haddad TC, Adelson K. Proposed Policy Changes to Cancer Care and Oncologic Drug Reimbursement: Exploring the Rationale and Anticipating the Consequences. American Society of Clinical Oncology Educational Book. 2025. doi:10.1200/edbk-25-473822

BibTeX
@article{Huey2025,
  author = {Huey, Ryan W and Pritchett, Joshua C and Vokinger, Kerstin N and Swenson, Wade and Haddad, Tufia C and Adelson, Kerin},
  title = {Proposed Policy Changes to Cancer Care and Oncologic Drug Reimbursement: Exploring the Rationale and Anticipating the Consequences},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2025},
  doi = {10.1200/edbk-25-473822}
}
Kostenlos starten →